presented by christopher sweeney at 2014 asco annual meeting
DESCRIPTION
E3805CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. Presented By Christopher Sweeney at 2014 ASCO Annual Meeting. A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer. - PowerPoint PPT PresentationTRANSCRIPT
<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Early Chemo+ADT: A debate in one slide – a need for randomized phase 3 trial
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
The CHAARTED Hypothesis
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
E3805 – CHAARTED Treatment
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Key Eligibility Criteria
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Study Endpoints
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Statistical Design: History of CHAARTED<br />Intent to treat analysis, 80% power 1-sided alpha=2.5% to detect 33% improvement in median OS (with all versions)
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Results:
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Patient characteristics
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Patient characteristics
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Patient characteristics
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Primary endpoint: Overall survival
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Causes of Death
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
OS by extent of metastatic disease at start of ADT
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
ADT + Docetaxel benefited all subgroups
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Secondary Endpoints
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Therapy beyond progression
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Chemotherapy Doses Given
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Non-Hematologic Toxicity (%)
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Hematologic Toxicity (%)
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Conclusion
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Clinical interpretation
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Designed and conducted by:
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting